![FDA](https://www.adcreviews.com/wp-content/uploads/2022/07/FDA-300x192.png)
FDA Delays Teplizumab License Application
RED BANK, N.J., June 30, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,
RED BANK, N.J., June 30, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,